Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Critical Care
Erschienen in: Critical Care 1/2002

01.02.2001 | Review

Bench-to-bedside review: Genetic influences on meningococcal disease

verfasst von: Clementien L Vermont, Ronald de Groot, Jan A Hazelzet

Erschienen in: Critical Care | Ausgabe 1/2002

Einloggen, um Zugang zu erhalten

Abstract

This review discusses the possible involvement of a variety of genetic polymorphisms on the course of meningococcal disease. It has been shown that several common genetic polymorphisms can either influence the susceptibility to meningococcal disease or can account for a higher mortality rate in patients. Gene polymorphisms concerning antibody receptors, lipopolysaccharide (LPS) binding receptors or proteins, innate complement proteins as well as cytokines and hemostatic proteins are described. The study of genetic polymorphisms might provide important insights in the pathogenesis of meningococcal disease and could make it possible to identify individuals who are at risk of either contrcting or dying from meningococcal disease.
Literatur
1.
Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM: Meningococcal disease. N Engl J Med. 2001, 344: 1378-1388. 10.1056/NEJM200105033441807.PubMedCrossRef
2.
Sim RJ, Harrison MM, Moxon ER, Tang CM: Underestimation of meningococci in tonsillar tissue by nasopharyngeal swabbing. Lancet. 2000, 356: 1653-1654. 10.1016/S0140-6736(00)03162-7.PubMedCrossRef
3.
Fogarty I, Cafferkey MT, Moloney AC: Meningococcal disease in the Republic of Ireland: 1995. Commun Dis Rep CDR Rev. 1997, 7: R9-R13.PubMed
4.
Anonymous: . Bacterial Meningitis in the Netherlands. 2001, Annual Report 1999. Amsterdam: Netherlands Reference Laboratory for Bacterial Meningitis.
5.
Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW: Genetic and environmental influences on premature death in adult adoptees. N Engl JMed. 1988, 318: 727-732.CrossRef
6.
Kwiatkowski D: Genetic dissection of the molecular pathogenesis of severe infection. Intensive Care Med. 2000, 26 (Suppl 1): S89-S97. 10.1007/s001340051124.PubMedCrossRef
7.
Kallstrom H, Liszewski MK, Atkinson JP, Jonsson AB: Membrane cofactor protein (MCP or CD46) is a cellular pilus receptor for pathogenic Neisseria. Mol Microbiol. 1997, 25: 639-647. 10.1046/j.1365-2958.1997.4841857.x.PubMedCrossRef
8.
Virji M, Alexandrescu C, Ferguson DJ, Saunders JR, Moxon ER: Variations in the expression of pili: the effect on adherence of Neisseria meningitidis to human epithelial and endothelial cells. Mol Microbiol. 1992, 6: 1271-1279.PubMedCrossRef
9.
Virji M, Makepeace K, Ferguson DJ, Watt SM: Carcinoembryonic antigens (CD66) on epithelial cells and neutrophils are receptors for Opa proteins of pathogenic neisseriae. Mol Microbiol. 1996, 22: 941-950. 10.1046/j.1365-2958.1996.01551.x.PubMedCrossRef
10.
de Vries FP, Cole R, Dankert J, Frosch M, van Putten JP: Neisseria meningitidis producing the Opc adhesin binds epithelial cell proteoglycan receptors. Mol Microbiol. 1998, 27: 1203-1212. 10.1046/j.1365-2958.1998.00763.x.PubMedCrossRef
11.
Stephens DS, Hoffman LH, McGee ZA: Interaction of Neisseria meningitidis with human nasopharyngeal mucosa: attachment and entry into columnar epithelial cells. J Infect Dis. 1983, 148: 369-376.PubMedCrossRef
12.
Stuart JM, Cartwright KA, Robinson PM, Noah ND: Effect of smoking on meningococcal carriage. Lancet. 1989, 2: 723-725. 10.1016/S0140-6736(89)90781-2.PubMedCrossRef
13.
Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ: A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol. 1991, 147: 1338-1343.PubMed
14.
Bredius RG, Derkx BH, Fijen CA, de Wit TP, de Haas M, Weening RS, van de Winkel JG, Out TA: Fc gamma receptor IIa (CD32) polymorphism in fulminant meningococcal septic shock in children. J Infect Dis. 1994, 170: 848-853.PubMedCrossRef
15.
Bredius RG, de Vries CE, Troelstra A, van Alphen L, Weening RS, van de Winkel JG, Out TA: Phagocytosis of Staphylococcus aureus and Haemophilus influenzae type B opsonized with polyclonal human IgG1 and IgG2 antibodies. Functional hFc gamma RIIa polymorphism to IgG2. J Immunol. 1993, 151: 1463-1472.PubMed
16.
Platonov AE, Shipulin GA, Vershinina IV, Dankert J, van de Winkel JG, Kuijper EJ: Association of human Fc gamma RIIa (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis. 1998, 27: 746-750.PubMedCrossRef
17.
Platonov AE, Kuijper EJ, Vershinina IV, Shipulin GA, Westerdaal N, Fijen CA, van de Winkel JG: Meningococcal disease and polymorphism of FcgammaRIIa (CD32) in late complement component-deficient individuals. Clin Exp Immunol. 1998, 111: 97-101. 10.1046/j.1365-2249.1998.00484.x.PubMedPubMedCentralCrossRef
18.
Fijen CA, Bredius RG, Kuijper EJ, Out TA, de Haas M, De Wit AP, Daha MR, De Winkel JG: The role of Fcgamma receptor polymorphisms and C3 in the immune defence against Neisseria meningitidis in complement-deficient individuals. Clin Exp Immunol. 2000, 120: 338-345. 10.1046/j.1365-2249.2000.01208.x.PubMedPubMedCentralCrossRef
19.
Figueroa JE, Densen P: Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991, 4: 359-395.PubMedPubMedCentral
20.
Thiel S, Vorup-Jensen T, Stover CM, Schwaeble W, Laursen SB, Poulsen K, Willis AC, Eggleton P, Hansen S, Holmskov U, Reid KB, Jensenius JC: A second serine protease associated with mannan-binding lectin that activates complement. Nature. 1997, 386: 506-510. 10.1038/386506a0.PubMedCrossRef
21.
Lipscombe RJ, Sumiya M, Hill AV, Lau YL, Levinsky RJ, Summer-field JA, Turner MW: High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum Mol Genet. 1992, 1: 709-715.PubMedCrossRef
22.
Madsen HO, Garred P, Kurtzhals JA, Lamm LU, Ryder LP, Thiel S, Svejgaard A: A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics. 1994, 40: 37-44.PubMedCrossRef
23.
Sumiya M, Super M, Tabona P, Levinsky RJ, Arai T, Turner MW, Summerfield JA: Molecular basis of opsonic defect in immun-odeficient children. Lancet. 1991, 337: 1569-1570. 10.1016/0140-6736(91)93263-9.PubMedCrossRef
24.
Lipscombe RJ, Sumiya M, Summerfield JA, Turner MW: Distinct physicochemical characteristics of human mannose binding protein expressed by individuals of differing genotype. Immunology. 1995, 85: 660-667.PubMedPubMedCentral
25.
Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M: Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet. 1999, 353: 1049-1053. 10.1016/S0140-6736(98)08350-0.PubMedCrossRef
26.
Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ: Structure and function of lipopolysaccharide binding protein. Science. 1990, 249: 1429-1431.PubMedCrossRef
27.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990, 249: 1431-1433.PubMedCrossRef
28.
Delude RL, Savedra R, Zhao H, Thieringer R, Yamamoto S, Fenton MJ, Golenbock DT: CD14 enhances cellular responses to endotoxin without imparting ligand-specific recognition. Proc Natl Acad Sci USA. 1995, 92: 9288-9292.PubMedPubMedCentralCrossRef
29.
Poltorak A, Smirnova I, He X, Liu MY, Van Huffel C, McNally O, Birdwell D, Alejos E, Silva M, Du X, Thompson P, Chan EK, Ledesma J, Roe B, Clifton S, Vogel SN, Beutler B: Genetic and physical mapping of the Lps locus: identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis. 1998, 24: 340-355. 10.1006/bcmd.1998.0201.PubMedCrossRef
30.
Beutler B: Endotoxin, toll-like receptor 4, and the afferent limb of innate immunity. Curr Opin Microbiol. 2000, 3: 23-28. 10.1016/S1369-5274(99)00046-6.PubMedCrossRef
31.
Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999, 189: 1777-1782. 10.1084/jem.189.11.1777.PubMedPubMedCentralCrossRef
32.
Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal. 2001, 13: 85-94. 10.1016/S0898-6568(00)00149-2.PubMedCrossRef
33.
Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Ritter M, Rothe G, Schmitz G: Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med. 2001, 29: 557-561. 10.1097/00003246-200103000-00015.PubMedCrossRef
34.
Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 2000, 25: 187-191. 10.1038/76048.PubMedCrossRef
35.
Smirnova I, Hamblin M, McBride C, Di Rienzo A: Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics. 2001, 158: 1657-1664.PubMedPubMedCentral
36.
Pridmore AC, Wyllie DH, Abdillahi F, Steeghs L, van der Ley P, Dower SK, Read RC: A lipopolysaccharide-deficient mutant of Neisseria meningitidis elicits attenuated cytokine release by human macrophages and signals via toll-like receptor (TLR) 2 but not via TLR4/MD2. J Infect Dis. 2001, 183: 89-96. 10.1086/317647.PubMedCrossRef
37.
Levin M, Quint PA, Goldstein B, Barton P, Bradley JS, Shemie SD, Yeh T, Kim SS, Cafaro DP, Scannon PJ, Giroir BP: Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet. 2000, 356: 961-967. 10.1016/S0140-6736(00)02712-4.PubMedCrossRef
38.
Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP, Vandenbrouke JP: Genetic influence on cytokine production and fatal meningo-coccal disease. Lancet. 1997, 349: 170-173. 10.1016/S0140-6736(96)06413-6.PubMedCrossRef
39.
Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987, i: 355-357. 10.1016/S0140-6736(87)91728-4.CrossRef
40.
Westendorp RG, Langermans JA, de Bel CE, Meinders AE, Vandenbroucke JP, van Furth R, van Dissel JT: Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J Infect Dis. 1995, 171: 1057-1060.PubMedCrossRef
41.
Stuber F, Petersen M, Bokelmann F, Schade U: A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med. 1996, 24: 381-384. 10.1097/00003246-199603000-00004.PubMedCrossRef
42.
Nadel S, Newport MJ, Booy R, Levin M: Variation in the tumor necrosis factor-alpha gene promoter region may be associated with death from meningococcal disease. J Infect Dis. 1996, 174: 878-880.PubMedCrossRef
43.
Read RC, Camp NJ, di Giovine FS, Borrow R, Kaczmarski EB, Chaudhary AG, Fox AJ, Duff GW: An interleukin-1 genotype is associated with fatal outcome of meningococcal disease. J Infect Dis. 2000, 182: 1557-1560. 10.1086/315889.PubMedCrossRef
44.
Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL: Relevance of the tumor necrosis factor alpha (TNF alpha)-308 promoter polymorphism in TNF alpha gene regulation. J Inflamm. 1996, 46: 32-41.
45.
Fang XM, Schroder S, Hoeft A, Stuber F: Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med. 1999, 27 (7): 1330-1334.PubMedCrossRef
46.
Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA: Increased plasma levels of interleukin-6 in sepsis. Blood. 1989, 74: 1704-1710.PubMed
47.
Takala A, Jousela I, Jansson SE, Olkkola KT, Takkunen O, Orpana A, Karonen SL, Repo H: Markers of systemic inflammation predicting organ failure in community-acquired septic shock. Clin Sci (Colch). 1999, 97: 529-538. 10.1042/CS19990073.CrossRef
48.
Harris MC, Costarino AT, Sullivan JS, Dulkerian S, McCawley L, Corcoran L, Butler S, Kilpatrick L: Cytokine elevations in critically ill infants with sepsis and necrotizing enterocolitis. J Pediatr. 1994, 124: 105-111.PubMedCrossRef
49.
50.
Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989, 169: 333-338.PubMedCrossRef
51.
Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993, 268: 10739-10745.PubMed
52.
Kornelisse RF, Hazelzet JA, Savelkoul HF, Hop WC, Suur MH, Borsboom AN, Risseeuw-Appel IM, van der Voort E, de Groot R: The relationship between plasminogen activator inhibitor-1 and proinflammatory and counterinflammatory mediators in children with meningococcal septic shock. J Infect Dis. 1996, 173: 1148-1156.PubMedCrossRef
53.
Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M: 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningo-coccal disease. Meningococcal Research Group. Lancet. 1999, 354: 556-560. 10.1016/S0140-6736(99)02220-5.PubMedCrossRef
54.
Westendorp RG, Hottenga JJ, Slagboom PE: Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet. 1999, 354: 561-563. 10.1016/S0140-6736(98)09376-3.PubMedCrossRef
55.
Menges T, Hermans PW, Little SG, Langefeld T, Boning O, Engel J, Sluijter M, de Groot R, Hempelmann G: Plasminogen- activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients. Lancet. 2001, 357: 1096-1097. 10.1016/S0140-6736(00)04311-7.PubMedCrossRef
56.
Hazelzet JA, Hermans PW: Hemostatic gene polymorphisms and meningococcal sepsis. Sepsis. 2001, 4: 233-237. 10.1023/A:1012965007673.CrossRef
Metadaten
Titel
Bench-to-bedside review: Genetic influences on meningococcal disease
verfasst von
Clementien L Vermont
Ronald de Groot
Jan A Hazelzet
Publikationsdatum
01.02.2001
Verlag
BioMed Central
Erschienen in
Critical Care / Ausgabe 1/2002
Elektronische ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc1454

Weitere Artikel der Ausgabe 1/2002

Critical Care 1/2002 Zur Ausgabe

Paper Report

Who should not receive noninvasive positive pressure ventilation

Review

Clinical review: A paradigm shift: the bidirectional effect of inflammation on bacterial growth. Clinical implications for patients with acute respiratory distress syndrome

Review

Clinical review: Non-antibiotic strategies for preventing ventilator-associated pneumonia

Editorial

Ethics and critical care in the new millennium

Meeting report

Eighth World Congress of Intensive and Critical Care Medicine, 28 October-1 November 2001, Sydney, Australia: Harm minimization and effective risk management

Review

Statistics review 1: Presenting and summarising data

Neu im Fachgebiet AINS

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Eingreifen von Umstehenden rettet vor Erstickungstod

15.05.2024 Fremdkörperaspiration Nachrichten

Wer sich an einem Essensrest verschluckt und um Luft ringt, benötigt vor allem rasche Hilfe. Dass Umstehende nur in jedem zweiten Erstickungsnotfall bereit waren, diese zu leisten, ist das ernüchternde Ergebnis einer Beobachtungsstudie aus Japan. Doch es gibt auch eine gute Nachricht.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren
Bildnachweise